Kensey Nash Corporation Report issue

For profit Phase 1 Phase 2
Founded: Exton PA United States (1984)
Status: Acquired by DSM (2012) → now Thermo Fisher Scientific (2017)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: Kensey Nash Corporation (0) Acquired (1)

allogeneic adipose derived mesenchymal stem cell (3 trials)

Drugs in Phase 1 Trials (3)

Key: Kensey Nash Corporation (0) Acquired (3)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

rhenium liposome (2 trials)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 4